Stem cell treatment of diabetes clinical transformation research by the national key projects

Medicine Network October 27th by Shanghai Jiaoda University School of Medicine affiliated Ruijin Hospital, Chinese Min People's Liberation Army Air Force Military Medical University affiliated Xijing Hospital, Beijing Jiyuan Biotech Co., Ltd. jointly declared the 2020 national key research and development plan "stem cell and transformation research" key special projects, human GLP-1 and FGF21 double-factor high-expression self-expressing fat-filled stem cell input treatment type 2 diabetes clinical research, in October was approved by the Ministry of Science and Technology.
approved project is "Human GLP-1 and FGF21 dual-factor high expression of interfactoral fat-filled stem cell input treatment type 2 diabetes clinical research", which is the first clinical research on diabetes since the 2016 "stem cell and transformation research" key project approval, is China's current stem cell and transformation research field of the highest level of national research projects.
lead unit, Ruijin Hospital, affiliated with Shanghai Jiao university medical school, was jointly developed by Xijing Hospital, affiliated with the Chinese MIN Air Force Military Medical University, and Beijing Jiyuan Biotech Co., Ltd.
Professor Cao Yanan of Shanghai Ruijin Hospital, who is in charge of the project, stressed that the overall goal of the research project is to further enhance the overall strength of stem cell clinical transformation research, establish a standardized and efficient high-quality operation model, and continuously enrich and enhance the scientific nature of results in clinical and basic research practice by exerting clinical potential and vitality, so as to better serve diabetic patients.
Hospital affiliated with Jiaojiao University is the National Center for Clinical Medicine of Metabolic Diseases, of which the National Hospital of Endocrine Metabolism Disease ranked first for nine consecutive years.
Cao Yanan said: For the topic to establish a specific scientific implementation plan, clear requirements, the task force will regularly hold the project implementation promotion meeting.
Through close cooperation between all parties, we will build a technical service platform for the clinical research of high-efficiency new drugs, especially in the early clinical research of biocellular innovative drugs and the safety assessment of the effectiveness of innovative drugs, and play a leading and exemplary role in the clinical transformation of modified stem cells for metabolic diseases in China.
is understood that the prevalence of diabetes in China is also showing a rapid growth trend, in 2017 China's 20 to 79-year-olds with diabetes patients 114.4 million, ranking first in the world.
type 2 diabetes as a metabolic disease has been included in the national major chronic disease management treatment plan.
Beijing JiyuanSheng Technology Co., Ltd. after many years of basic research, the use of "human GLP-1 and FGF21 dual-factor high expression of interfaith fat-filled stem cell input treatment type 2 diabetes" made a major breakthrough, at home and abroad in a leading position, access to national invention patents.
also applied for international patents such as the United States, the research project has passed the stem cell clinical research record safety evaluation and began to enter preclinical research and start the IND filing process.